The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / What Causes Nephrogenic Systemic Fibrosis?

What Causes Nephrogenic Systemic Fibrosis?

September 1, 2007 • By Jonathan Kay, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Jonathan Kay, MD
“Europa” by Paul Klee. Klee developed scleroderma toward the end of his life, which greatly influenced his later works.

In August 2001, Diane Endicott* noted the spontaneous onset of tightening of the skin over her feet and lower legs. Endicott was a 40-year-old woman with type 1 insulin-dependent diabetes mellitus which started at age 10 and stage 5 chronic kidney disease (kidney failure with glomerular filtration rate less than 15 mL/min/1.73 m2 or receiving dialysis), who had been on hemodialysis for the previous two years. This skin tightening progressed rapidly to involve the skin on her thighs, hands, and forearms. It also involved the skin over her breasts and in her perineal region. She observed the skin in these areas to be thickened and tethered to the underlying tissue and darker in color than her skin elsewhere.

You Might Also Like
  • Gadolinium Compounds Provide Insights into Pathogenesis of Fibrosing Diseases
  • 2013 ACR/ARHP Annual Meeting: Strides Made in Understanding Systemic Sclerosis
  • The Role of Macrophages in Inflammation & Fibrosis: Macrophages May Predict Progressive Skin Disease
Explore This Issue
September 2007

Her fingers became fixed in flexion. Her hands became claw-like, causing her difficulty buttoning her blouse, and she developed fixed flexion contractures of her knees. (See Fig. 1) Because she could not fully extend either leg, she no longer was able to walk independently and required the use of a wheelchair to move. She also developed conjunctival erythema and yellow scleral plaques. As her skin changes progressed to extend above her elbows, Endicott also developed fixed flexion contractures of her elbows and she became incapacitated by severe, burning pain in her extremities that kept her awake at night. However, she noted no tightening of the skin on her face and had never experienced color change of her digits upon cold exposure.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Endicott’s nephrologist was puzzled by the rapid onset of this scleroderma-like condition, having never seen this before among the other patients receiving dialysis under his care. To clarify Endicott’s diagnosis, he referred her to the rheumatology consultant at his hospital. The consultant had seen patients with scleroderma develop renal failure during scleroderma renal crisis. However, he, too, had never observed a patient with pre-existing stage 5 chronic kidney disease develop the new onset of cutaneous changes of scleroderma. Thus, he referred Endicott to a nearby academic medical center for dermatologic evaluation and for another rheumatologic opinion.

Early Cases

During the preceding four years, between May 1997 and November 2000, eight of 265 patients who had received renal allografts at Sharp Memorial Hospital in San Diego developed the relatively rapid onset of skin changes similar to Endicott’s and that resembled scleromyxedema. Each of these eight patients developed fibrotic skin changes on the trunk and extremities, which resulted in debilitating joint contractures. However, none developed facial involvement or had the circulating IgG lambda paraprotein that would be expected in scleromyxedema.1 Skin biopsies from each of these patients were sent to Philip E. LeBoit, MD, professor of clinical pathology and dermatology at the University of California, San Francisco. Along with his fellow, Shawn E. Cowper, MD, now assistant professor of dermatology and pathology at Yale University School of Medicine in New Haven, Conn., and other colleagues, he examined these biopsies and observed histologic features similar to one another but that were unique.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions, Scleroderma Tagged With: case report, Diagnostic Criteria, kidney, Nephrogenic Systemic Fibrosis, Pathogenesis, TreatmentIssue: September 2007

You Might Also Like:
  • Gadolinium Compounds Provide Insights into Pathogenesis of Fibrosing Diseases
  • 2013 ACR/ARHP Annual Meeting: Strides Made in Understanding Systemic Sclerosis
  • The Role of Macrophages in Inflammation & Fibrosis: Macrophages May Predict Progressive Skin Disease
  • Research Links Macrophages with Pathogenesis of Inflammation, Fibrosis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.